ArticleClinical cardiology2026
Correlation Between the High-Sensitivity C-Reactive Protein-to-Albumin Ratio and All-Cause Mortality in Patients With Acute Exacerbation of Chronic Heart Failure.
Article in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the correlation between the high-sensitivity C-reactive protein-to-albumin ratio (CAR) and all-cause mortality in patients with acute exacerbation of chronic heart failure (AECHF).
methodsIn this retrospective cohort study, 342 patients were enrolled from the First People's Hospital of Zhenjiang City between January 1, 2020, and December 31, 2025. Cox regression analyses, subgroup analyses, Kaplan-Meier survival curves, and receiver operating characteristic (ROC) analyses were employed to assess the association between CAR and all-cause mortality.
resultsDuring a median follow-up period of 16.35 months, 95 patients (27.8%) died. Multivariate Cox regression analysis revealed that each unit increase and each standard deviation increase in CAR were associated with a 41.2% and 40.7% increased risk of all-cause mortality, respectively (HR: 1.412, 95% CI: 1.221-1.633; HR: 1.407, 95% CI: 1.219-1.625). The risk of all-cause mortality in the high CAR group was 1.778 times that of the low CAR group (HR: 1.778; 95% CI: 1.092-2.894). The robustness of the association between CAR and all-cause mortality was further corroborated by subgroup and sensitivity analyses (p < 0.05). Kaplan-Meier survival curves revealed significant survival differences across CAR subgroups, with markedly lower cumulative survival observed in the high-CAR group (p < 0.05). ROC curve indicated a weak but statistically significant predictive value for all-cause mortality risk (p = 0.025).
conclusionHigher levels of CAR are associated with a higher risk of all-cause mortality in AECHF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.